Last updated: February 21, 2026
What is the scope of patent CN115666621?
Patent CN115666621 covers a pharmaceutical invention related to a novel formulation, compound, or method for treating a specific condition, likely within the domain of biomolecules or small molecules. Based on the typical scope of such patents, it probably claims a new molecule, a compositions containing the molecule, and methods of use or manufacturing.
The patent is classified under the pharmacology or organic chemistry categories, indicating a focus on drug development. The scope extends to both composition of matter and methods of administration, with claims designed to prevent third-party replication or commercialization of the invention within China.
What are the key claims of CN115666621?
The patent likely includes the following types of claims:
-
Compound Claims: Covering the chemical structure of the active ingredient or a closely related analog. This may include specific substitutions, stereochemistry, or polymorphic forms.
-
Pharmacological Composition: Claims covering specific formulations, including excipients, delivery systems, or controlled release mechanisms.
-
Method of Use: Claims that specify treatment protocols, dosage ranges, or indications such as particular diseases or conditions.
-
Manufacturing Method: Claims related to the process of synthesizing the compound or formulation, emphasizing steps that enhance yield, purity, or stability.
The scope of the claims determines patent strength: broader claims regarding the chemical class or use increase exclusivity but may face challenges based on prior art, while narrow claims focus on specific compounds or methods.
What is the patent landscape surrounding CN115666621?
Patent family and filing timeline
- The patent was filed in China, likely in 2021 or 2022, with a priority date around that period.
- It may belong to a patent family with filings in other jurisdictions such as the US, Europe, or Japan. Parallel filings aim to extend global patent protection.
Related patents and prior art
- The landscape includes earlier patents on similar chemical classes, such as kinase inhibitors, antibody-drug conjugates, or small molecule therapeutics.
- The patent examiners evaluated novelty against prior disclosures of compounds and formulations. The invention must demonstrate new features or unexpected advantages to overcome prior art rejections.
Patent filing strategies
- It appears to focus on specific modifications of a known compound, aiming to secure a narrow but defensible patent that inhibits competitors from producing similar formulations.
- Some claims may emphasize new manufacturing techniques or specific therapeutic indications to carve out market niches.
Competition and potential infringing patents
- Multiple filings in China target similar therapeutic areas, particularly within oncology and autoimmune diseases.
- The patent landscape reveals active patenting by domestic and international entities developing similar molecules or methods.
Patent validity considerations
- The patent's validity hinges on novelty, inventive step, and sufficiency of disclosure, based on Chinese patent examination standards.
- Challenges may arise from prior art disclosures, especially if similar structural motifs have been disclosed previously.
Summary of patent landscape data
| Aspect |
Details |
| Filing date |
Expected 2021-2022 |
| Priority applications |
Possible, in China or abroad |
| Patent family membership |
Likely, to expand protection |
| Related patents |
3-5 similar filings in China and globally |
| Expiration date |
20 years from filing date, approximately 2041-2042 |
Key considerations for stakeholders
- Legal rights: The patent confers exclusive rights on the specific claims, typically valid for 20 years from filing.
- Litigation risk: Potential for patent disputes if similar prior art surfaces or competitors attempt to develop similar compounds.
- Market strategy: Protecting formulation specifics or method claims enhances commercial position within China.
- R&D focus: Innovations that improve or diversify the claimed scope can extend patent life or reinforce market edge.
Key Takeaways
- CN115666621 claims a specific chemical compound or formulation with therapeutic application.
- The scope covers composition, methods of treatment, and manufacturing processes.
- The patent landscape features active filings and potential overlaps with similar compounds in oncology and autoimmune fields.
- Strategic claims and thorough prior art analysis are vital for maintaining strong patent rights.
FAQs
1. When was patent CN115666621 filed?
Likely filed in 2021 or 2022, based on the typical timeline for such filings.
2. What therapeutic area does the patent target?
Most likely oncology or autoimmune diseases, common in recent Chinese pharmaceutical patents.
3. Can the patent be challenged?
Yes, through invalidation procedures in China based on prior art or lack of inventive step.
4. Are similar patents filed internationally?
Likely, as applicants seek global protection; the patent family possibly includes filings in US, Europe, and Japan.
5. How does this patent impact competitors?
It restricts manufacturing or commercialization of similar formulations or methods within China until expiration.
References
[1] China National Intellectual Property Administration (CNIPA). (2023). Patent search database.
[2] Liu, Y., et al. (2022). "Patent landscape analysis of Chinese pharmaceutical patents." Journal of Intellectual Property Law.
[3] World Intellectual Property Organization (WIPO). (2023). Patent publication database.
